БЛД

18.ОвсянниковД.Ю.Беляшова, М.А.Зайцева, Н.О.идр.Редкое

21.SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Finer N.N., Carlo W.A., Walsh M.C. et al. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 2010; 362: 1970–79.

22.Sandri F., Plavka R., Ancora G. et al. CURPAP Study Group: Prophylactic or early selective surfactant combined with nCPAP in very preterm infants. Pediatrics 2010; 125:e1402– e1409.

23.Rojas-Reyes M.X., Morley C.J., Soll R. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2012:CD000510.

24.Stevens T.P., Harrington E.W., Blennow M. et al. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 2007:CD003063.

25.Verder H., Robertson B., Greisen G. et al. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. Danish-Swedish Multicenter Study Group. N Engl J Med 1994; 331: 1051–55.

26.Sweet D.G., Carnielli V., Greisen G. et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants – 2013 update. Neonatology 2013; 103:353–68.

27.Morley C.J. Volume-limited and volumetargeted ventilation. Clin Perinatol 2012;

39:513–23.

28.Wheeler K., Klingenberg C., McCallion N. et al. Volume-targeted versus pressurelimited ventilation in the neonate. Cochrane Database Syst Rev 2010:CD003666.

29.Erickson S.J., Grauaug A., Gurrin L. et al. Hypocarbia in the ventilated preterm infant and its effect on intraventricular haemorrhage and bronchopulmonary dysplasia J Paediatr Child Health 2002; 38: 560–562.

30.The STOP-ROP Multicenter Study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity, a randomized, controlled trial. Pediatrics 2000;105:295– 310.

31.Askie L.M., Henderson-Smart D.J., Irwig L. et al. Oxygen saturation targets and outcomes in extremely preterm infants. N. Engl. J. Med. 2003; 349: 959–67.

32.SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Carlo W.A., Finer N.N., Walsh M.C. et al: Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med 2010; 362: 1959–69.

33.Stenson B., Brocklehurst P., Tarnow-Mordi W. Increased 36-week survival with high oxygen saturation target in extremely preterm infants N Engl J Med 2011; 364: 1680–1682.

34.Nievas F.F., Chernick V. Bronchopulmonary dysplasia: an update for the pediatrician. Clin. Pediatr. 2002; 41: 77–85.

35.Подготовкабольныхсреспиртологиекаторнойвиап. релетам

36.Schmidt B., Roberts R.S., Davis P. et al. Caffeine for Apnea of Prematurity Trial Group: Caffeine therapy for apnea of prematurity N Engl J Med 2006; 354: 2112–21.

37.Henderson-Smart D.J., Davis P.G. Prophylactic methylxanthines for endotracheal extubation in preterm infants. Cochrane Database Syst Rev 2010:CD000139.

38.Halliday HL, Ehrenkranz RA, Doyle LW: Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2010:CD001146

39.Halliday HL, Ehrenkranz RA, Doyle LW: Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009:CD001145

40.Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC: Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease Pediatrics 2005; 115: 655–661

41.БабакО.А.Воронцова, Ю.Н.Геппе, Н.А.и,др.Бронхолегочнаядисплазия.

ИздательствоГОУВПОРГМУРосздрава, 2010: 56.

42.Doyle LW, Davis PG, Morley CJ, et al. Low-Dose Dexamethasone Facilitates Extubation Among Chronically Ventilator-Dependent Infants: A Multicenter, International, Randomized, Controlled Trial. Pediatrics. 2006; 117:75-83.

43.Onland W, Offringa M, Jaegere A. P. De, van Kaam AH. Finding the Optimal Postnatal Dexamethasone Regimen for Preterm Infants at Risk of Bronchopulmonary Dysplasia: A Systematic Review of Placebo-Controlled Trials. Pediatrics. 2009; 123 (1):367-77.

57.ДавыдоваИ.В.Форм,течениеисходыровабронхолегочнойдисплазииие

удетей.Автореф.дисс….мнМ., 2010: 48

58.Pandit PB, Dunn MS, Kelly EN, Perlman M: Surfactant replacement in neonates with early chronic lung disease. Pediatrics 1995; 95: 851–4.

59.Checchia P.A., Nalysnyk L., Fernandes A. W., et al. Mortality and and morbidity among infants at high risk for severe respiratory syncytial virus infection receving prophilaxis with palivizumab: A systematic literature review and meta-analysis. Pediatr Crit Care Med. 2011; 12 (5): 580-8.

61.ЯнгТ.Мангум, Б.Неофакс2006.Веретея: , .2006: 332.

62.Mourani P M, Sontag M K, Dunbar Ivy D, et al. Effects of Long-term Sildenafil Treatment for Pulmonary Hypertension in Infants with Chronic Lung Disease. J Pediatr. 2009; 154(3): 379–384.e2.

63.ДегтяреваЕА,ОвсяннЮ,ЗайцеваНО.и,дрков.Легипертензияочная

легочноесердцудетейбронхолегочнойдисплаз:факторыриска, ейагностика,

64.Steinhorn RH, Kinsella JP, Pierce C, et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr. 2009; 155: 841.

65.Современнподхкпр д,фыиагностлактикелечен кею

66.ТаточеВ.К.Вакцинацияедоношенныхкомаловдетей. сных

67.Tommiska V., Heinonen K., Kero P., et al. A national two year follow up study of extremely low birthweight infants born in 19961997. Arch. Dis. Child. Fetal. Neonatal. Ed 2003;88:F29.

68.СтоллБ.Дж.К, Р.игманМ.Поражениядыхательныхпутей.Вкн.Берман: Р.

formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics. 2007;120(6):1260-69.

70. БойцЕ.В., огдановаА.В.Овсянников, Д.Ю.Последствия

бронхолегочнойдисплаздляреспздоровьяииратдетей,п рндримогостковлдых